CAG repeat number governs the development rate of pathology in Huntington's disease. - Wikidata - awgldk - TriplyDB

CAG repeat number governs the development rate of pathology in Huntington's disease.

CAG repeat number governs the development rate of pathology in Huntington's disease.

http://www.wikidata.org/entity/Q45294278

about

Physiotherapy clinical guidelines for Huntington’s disease Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling.Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease.Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study Huntington’s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer’s disease Disruption of response inhibition circuits in prodromal Huntington disease.Phonatory dysfunction as a preclinical symptom of Huntington disease.Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration.Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study.Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo.Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study Functional magnetic resonance imaging of working memory in Huntington's disease: cross-sectional data from the IMAGE-HD study.Dynamics of the connectome in Huntington's disease: A longitudinal diffusion MRI study.Functional changes during working memory in Huntington's disease: 30-month longitudinal data from the IMAGE-HD study.Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.Robust MR-based approaches to quantifying white matter structure and structure/function alterations in Huntington's disease.Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.Tractography of the corpus callosum in Huntington's disease.Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function.Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease.Neural correlates of impaired emotion processing in manifest Huntington's disease.Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation.QEEG Measures in Huntington's Disease: A Pilot Study.Atomistic simulations of the effects of polyglutamine chain length and solvent quality on conformational equilibria and spontaneous homodimerization A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.No evidence of impaired gastric emptying in early Huntington's Disease.Fetal striatal grafting slows motor and cognitive decline of Huntington's disease.What is the impact of education on Huntington's disease?Nitric oxide and nitric oxide synthase in Huntington's disease.Age-at-onset in Huntington disease.The selective vulnerability of nerve cells in Huntington's disease.Deep white matter in Huntington's disease Tracking motor impairments in the progression of Huntington's disease.

P2860

Q22305764-6CEC158E-2D78-4E69-92DF-899B11FDC5B8 Q24307941-1808798E-54F4-4EC1-A962-62870A8251FA Q24598264-3AF17B0B-AFD6-423B-91B4-9B50087ADF52 Q27317122-926FDE74-BF44-46AC-AE93-114C268AEB63 Q27333729-090A8FE7-9E01-408B-AE57-BDE601E1F88F Q28393234-D83D6E1F-C19D-4F94-A3BD-4EE70FB547F7 Q29248581-9236C122-8372-4894-9147-B67B55F65DA3 Q30403689-774756E5-E85A-4652-A11A-2B0E4C8DB599 Q30425545-A6036ACF-3C20-4C21-93DF-471549DB3D88 Q30427825-3A3340DD-5BEA-4EE1-99E0-CAE0E82AE70C Q30441887-14CC1F33-CE50-4AE1-A630-8FDD33602259 Q30494325-9E69A139-8CFC-483B-A75D-9FCF21F8E254 Q30577157-EBE7FE64-8DE6-4D32-861C-23716910E440 Q30631995-C2698EF3-2A32-4E52-8ED5-D51212A0C086 Q30659199-C5AB81F2-620E-4929-BF18-82B39535C066 Q30661031-E78DCB1B-27A5-4FBE-8294-75D7274C7A04 Q30696281-6529A12A-4881-434D-86E8-66FFD5332E4B Q30855262-EE44F940-BDC6-423A-B84D-E2C60469B300 Q30991345-3A07AB29-646E-4E1F-8BC4-37434D4B2C84 Q31002507-F984E42E-7C06-4F8F-B9FA-46E20CB6E8D0 Q31137452-1EBFAD88-EBDB-4DC1-9779-EEAC3DD0CAD9 Q33489152-20956B86-6D2D-44F4-AE9B-22E5459CC444 Q33562672-0D0E5350-B119-4B43-982C-8766AB11E4AA Q33564443-14DD1D56-0CBC-415B-B044-7AFC0F7BD0FE Q33579030-A7280424-49CF-48C8-A7FE-CE69170689E9 Q33582389-E822300C-49CF-418C-AB2C-76B27DFD5D85 Q33644718-6C890EB3-7062-4C2E-9C44-8427CD7B8CC8 Q33694463-7424E0CF-A24B-43C4-8C76-217F4CCE09E8 Q33734662-821E1E21-DE38-4FD6-A15B-83C84F5B6002 Q33761386-52BD0457-AEB1-4474-B813-D740D1BD8C5A Q33929560-09953A8E-3A4E-49BF-AF8E-F30347E6327B Q33931283-A42BAE58-18B1-4AA7-A506-A87B4B9461E9 Q34087126-3B6B72BA-15D6-4089-BC76-0C82D21CC8DB Q34092359-4DE92B66-16B5-4CFE-ACB3-17BE84921007 Q34172955-0FD221E2-69C5-4178-BF98-9D7BBFE58BFF Q34208531-57CB7AC7-E311-450B-B23C-52B9DE70294E Q34210139-3A8E58AA-609C-4FE4-B40E-E5816776D0CC Q34216757-CA53FCB1-2629-4934-87AC-AC424BC86A8E Q34394979-A7CC9682-B786-4DD9-9C5F-A400CA8FCACE Q34449476-029A758C-F7DE-4160-9035-4C2282E6FEC6

P2860

CAG repeat number governs the development rate of pathology in Huntington's disease.

http://www.wikidata.org/entity/Q45294278

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年学术文章

@wuu

1997年学术文章

@zh

1997年学术文章

@zh-cn

1997年学术文章

@zh-hans

1997年学术文章

@zh-my

1997年学术文章

@zh-sg

1997年學術文章

@yue

1997年學術文章

@zh-hant

name

CAG repeat number governs the development rate of pathology in Huntington's disease.

@en

CAG repeat number governs the development rate of pathology in Huntington's disease.

@nl

type

label

CAG repeat number governs the development rate of pathology in Huntington's disease.

@en

CAG repeat number governs the development rate of pathology in Huntington's disease.

@nl

prefLabel

CAG repeat number governs the development rate of pathology in Huntington's disease.

@en

CAG repeat number governs the development rate of pathology in Huntington's disease.

@nl

P1433

Q45294278-3C6C9E55-6BD2-4426-B73A-6CE2E77DBC29

P1476

Q45294278-B4BE0229-FD4D-4A9A-8C6C-FE5A7FD19BB8

P2093

Q45294278-7913A92D-66AD-4F50-B796-C8E430697F60

Q45294278-D861D2FE-300B-4990-9327-A6F506611796

Q45294278-E76BC7DC-8182-4293-89E9-63C6C47AB4D8

P2860

Q45294278-49E4B2D8-5742-4C66-B71F-3D6ED010AB6B

Q45294278-7A5EA031-C4AB-45C3-87C6-0ADBFF05E196

Q45294278-BA6C1744-7131-49D2-B36D-E64C7B365FBE

Q45294278-E59F0866-3878-4A6C-85D4-1B635315E4FD

P304

Q45294278-3043C585-F8F2-4698-9375-639F2EEBB7E2

P31

Q45294278-7C3F451E-CE5C-4334-B164-2BD687D82366

P356

Q45294278-C62A145C-46D6-4CB4-8EBA-EA058A2994A8

P433

Q45294278-AFABF905-689E-4B71-B4E0-291EBB0C742E

P478

Q45294278-ED4EDECE-4DB0-4316-B96A-97E7FDD7F7B9

P50

Q45294278-906484C9-5CFF-4535-911B-7453A01D751D

Q45294278-DA66016E-430A-460A-8F83-401DC93EA6A8

P577

Q45294278-0AD0BE1B-C59A-4BF8-9B0B-58930AAC0E99

P698

Q45294278-6F1E4FAC-F7A2-4C56-98E4-1ACC8D9BE50C

P921

Q45294278-30861BC8-98FF-4F4B-A4AC-A141C2EDFBE8

Q45294278-facc535f-61d2-40f6-9cf2-aba4a0374b9c

P356

P1433

Annals of Neurology

P1476

CAG repeat number governs the development rate of pathology in Huntington's disease.

@en

P2093

MacDonald ME

http://www.w3.org/2001/XMLSchema#string

Penney JB Jr

http://www.w3.org/2001/XMLSchema#string

Vonsattel JP

http://www.w3.org/2001/XMLSchema#string

P2860

Unimpaired verbal memory and oculomotor control in asymptomatic adults with the genetic marker for Huntington's disease.

Trinucleotide repeat length and clinical progression in Huntington's disease.

The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease.

Development of neuropsychological deficits in Huntington's disease.

P304

689-692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.410410521

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

James F. Gusella

Richard H Myers

P577

1997-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9153534

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease